Dissolution in nasal fluid, retention and anti-inflammatory activity of fluticasone furoate in human nasal tissue ex vivo

Clinical and Experimental Allergy

Volumn 39, Issue 10, 2009, Pages 1540-1550

  Baumann, D ^a   Bachert, C ^b   Hogger P ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Glucocorticoids; Human nasal tissue; Pharmacodynamics; Pharmacokinetics; Rhinitis

Indexed keywords

BUDESONIDE; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; INTERLEUKIN 8; MOMETASONE FUROATE; TRIAMCINOLONE ACETONIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DESORPTION; DISSOLUTION; DRUG ADSORPTION; DRUG BINDING; DRUG CLEARANCE; DRUG RETENTION; DRUG SOLUBILITY; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; NOSE MUCOSA; NOSE MUCUS; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; BODY FLUIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; NOSE; SOLUBILITY; TISSUE CULTURE TECHNIQUES;

EID: 70349141708     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2009.03306.x     Document Type: Article

References (45)

1. Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008 63 (Suppl. 86) : 8 160.
2. Fokkens WJ, Jogi R, Reinartz S et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 2007 62 : 1078 1084.
3. Rosenblut A, Bardin PG, Muller B et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy 2007 62 : 1071 1077.
4. Kaiser HB, Naclerio RM, Given J, Toler TN, Ellsworth A, Philpot EE. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007 119 : 1430 1437. (Pubitemid 46855849)
5. Nathan RA, Berger W, Yang W et al. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2008 100 : 497 505.
6. Anolik R, Nathan RA, Schenkel E, Danzig MR, Gates D, Varghese S. Intranasal mometasone furoate alleviates the ocular symptoms associated with seasonal allergic rhinitis: results of a post hoc analysis. Int Arch Allergy Immunol 2008 147 : 323 330.
7. Valotis A, Högger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res 2007 8 : 54.
8. Salter M, Biggadike K, Matthews JL et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007 293 : L660 7.
9. Hochhaus G. Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: potential effects on clinical safety and efficacy. Clin Ther 2008 30 : 1 13.
10. Esmailpour N, Högger P, Rohdewald P. Binding of glucocorticoids to human nasal tissue in vitro. Int Arch Allergy Immunol 2000 122 : 151 154.
11. Bonsmann U, Bachert C, Delank KW, Rohdewald P. Presence of fluticasone propionate on human nasal mucosal surface and in human nasal tissue over a period of 24 h after intranasal application. Allergy 2001 56 : 532 535.
12. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy 2008 63 : 1292 1300.
13. Wagenmann M, Schumacher L, Bachert C. The time course of the bilateral release of cytokines and mediators after unilateral nasal allergen challenge. Allergy 2005 60 : 1132 1138.
14. Bachert C, Wagenmann M, Hauser U. Proinflammatory cytokines: measurement in nasal secretion and induction of adhesion receptor expression. Int Arch Allergy Immunol 1995 107 : 106 108.
15. Ural A, Tezer MS, Yucel A, Atilla H, Ileri F. Interleukin-4, interleukin-8 and E-selectin levels in intranasal polyposis patients with and without allergy: a comparative study. J Int Med Res 2006 34 : 520 524.
16. Xu R, Xu G, Shi J, Wen W. A correlative study of NF-kappaB activity and cytokines expression in human chronic nasal sinusitis. J Laryngol Otol 2007 121 : 644 649.
17. Otto BA, Wenzel SE. The role of cytokines in chronic rhinosinusitis with nasal polyps. Curr Opin Otolaryngol Head Neck Surg 2008 16 : 270 274.
18. Wu J, Bing L, Jin H, Jingping F. Gene expression profiles of nasal polyps associated with allergic rhinitis. Am J Otolaryngol 2009 30 : 24 32.
19. Lorin MI, Gaerlan PF, Mandel ID. Quantitative composition of nasal secretions in normal subjects. J Lab Clin Med 1972 80 : 275 281.
20. Eichner H. Present possibilities for diagnosis in human nasal secretions. Rhinology 1983 21 : 223 228.
21. Knowles MR, Robinson JM, Wood RE et al. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects. J Clin Invest 1997 100 : 2588 2595.
22. Verkman AS, Song Y, Thiagarajah JR. Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease. Am J Physiol Cell Physiol 2003 284 : C2 15.
23. Smith PK, Krohn RI, Hermanson GT et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985 150 : 76 85.
24. Ruocco L, Fattori B, Romanelli A et al. A new collection method for the evaluation of nasal mucus proteins. Clin Exp Allergy 1998 28 : 881 888.
25. Mehl E, Plambeck J, Lottspeich F. Probenvorbereitung von Protein-Mikromengen: Maßnahmen gegen Adsorptionsverluste. In : Engelhardt H, Lottspeich F, Reh E, Schneider H-J, Uihlein M, eds. Kapillarelektrophorese- Chromatographie; Würzburger Kolloquium; Fortschrittsberichte '93. Straubing : Bertsch Verlag, 1993 189 195.
26. David HA, Hartley HO, Pearson ES. The distribution of the ratio, in a single normal sample of the range to standard deviation. Biometrika 1954 41 : 482 493.
27. Pearson ES, Stephens MA. The ration of range to standard deviation in the same normal sample. Biometrika 1964 51 : 484 487.
28. Block LH, Patel RN. Solubility and dissolution of triamcinolone acetonide. J Pharm Sci 1973 62 : 617 621.
29. Högger P, Rohdewald P. Glucocorticoid receptors and fluticasone propionate. Rev Contemp Pharmacother 1998 9 : 501 522.
30. Pham S, Wiedmann TS. Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant. J Pharm Sci 2001 90 : 98 104.
31. Lexmüller K, Gullstrand H, Axelsson BO et al. Differences in endogenous esterification and retention in the rat trachea between budesonide and ciclesonide active metabolite. Drug Metab Dispos 2007 35 : 1788 1796.
32. Lindemann J, Keck T, Scheithauer MO, Leiacker R, Wiesmiller K. Nasal mucosal temperature in relation to nasal airflow as measured by rhinomanometry. Am J Rhinol 2007 21 : 46 9.
33. Würthwein G, Rohdewald P. Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate. Biopharm Drug Dispos 1990 11 : 381 394.
34. Esmailpour N, Högger P, Rohdewald P. Binding kinetics of budesonide to the human glucocorticoid receptor. Eur J Pharm Sci 1998 6 : 219 223.
35. Valotis A, Neukam K, Elert O, Högger P. Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. J Pharm Sci 2004 93 : 1337 1350.
36. Vidgren MT, Kublik H. Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev 1998 29 : 157 177.
37. Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today 2002 7 : 967 975.
38. Thorsson L, Borga O, Edsbacker S. Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder. Br J Clin Pharmacol 1999 47 : 619 624.
39. Khanvilkar K, Donovan MD, Flanagan DR. Drug transfer through mucus. Adv Drug Deliv Rev 2001 48 : 173 193.
40. Erin EM, Zacharasiewicz AS, Nicholson GC et al. Topical corticosteroid inhibits interleukin-4, -5 and -13 in nasal secretions following allergen challenge. Clin Exp Allergy 2005 35 : 1608 1614.
41. Teng XW, Cutler DJ, Davies NM. Mometasone furoate degradation and metabolism in human biological fluids and tissues. Biopharm Drug Dispos 2003 24 : 321 333.
42. Valotis A, Högger P. Significant receptor affinities of metabolites and a degradation product of mometasone furoate. Respir Res 2004 5 : 7.
43. Allen A, Down G, Newland A et al. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Clin Ther 2007 29 : 1415 1420.
44. Daley-Yates PT, Kunka RL, Yin Y, Andrews SM, Callejas S, Ng C. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol 2004 60 : 265 268.
45. Argenti D, Colligon I, Heald D, Ziemniak J. Nasal mucosal inflammation has no effect on the absorption of intranasal triamcinolone acetonide. J Clin Pharmacol 1994 34 : 854 858.